CN111939268B - Nano particle compound for responsive deformation of tumor microenvironment - Google Patents
Nano particle compound for responsive deformation of tumor microenvironment Download PDFInfo
- Publication number
- CN111939268B CN111939268B CN201910396302.8A CN201910396302A CN111939268B CN 111939268 B CN111939268 B CN 111939268B CN 201910396302 A CN201910396302 A CN 201910396302A CN 111939268 B CN111939268 B CN 111939268B
- Authority
- CN
- China
- Prior art keywords
- polylysine
- drug conjugate
- tumor
- oligomeric polypeptide
- amphiphilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a nano particle compound with responsive deformation of tumor microenvironment, which is formed by combining an amphiphilic oligomeric polypeptide drug conjugate and beta-carboxamide polylysine through electrostatic interaction. The amphiphilic oligomeric polypeptide drug conjugate is a product obtained by condensing anticancer drug adriamycin and oligomeric polypeptide KIGLFRWR through chemical bonds. The nano particle compound can be passively gathered at a tumor position in a targeted manner, a beta-carboxylic acid amide group connected to polylysine is broken under the acidic pH condition of a tumor area, the charge of the polylysine is changed from negative charge to positive charge and is repelled with an amphiphilic oligomeric polypeptide drug conjugate with positive charge, so that the nano particle compound is dissociated, and then the amphiphilic oligomeric polypeptide drug conjugate can be further assembled into long fibers, so that the long-time retention at the tumor position is realized, the drug adriamycin is slowly released, and the high-efficiency anticancer effect is realized.
Description
Technical Field
The invention relates to the field of medicinal preparations, in particular to a nano particle compound with responsive deformation of tumor microenvironment, which is formed by combining an amphiphilic oligomeric polypeptide drug conjugate and beta-carboxamide polylysine through electrostatic interaction.
Background
Cancer is the second leading cause of death worldwide, with 429 ten thousand of new tumor cases in China in 2015, accounting for 2145 ten thousand of new tumor cases worldwide in this year; the number of the global tumor death cases in the same year reaches 880 ten thousand, wherein the number of the tumor death cases in China reaches 281 ten thousand, and the death rate is the top of the world leaderboard. Although human beings have made good progress in antitumor therapy in the last decades, cytotoxic chemotherapeutic drugs (such as adriamycin and the like) which are commonly used for tumor therapy in clinic still have the problems of poor targeting, difficult accumulation of tumor parts and the like, and serious adverse reactions and toxic and side effects. How to improve the toxic and side effects and improve the in vivo pharmacokinetic behavior of the traditional Chinese medicine is a hot point of research of people.
The polypeptide-drug conjugate composed of the drug, the functional polypeptide sequence and the degradable connecting bond is a novel strategy for improving the physicochemical property of the drug, and has the advantages of high biocompatibility, easy biodegradation, simple preparation and the like. In addition, through the sequence design of the polypeptide constructed by different amino acids, the polypeptide can be regulated and controlled to form different shapes such as fibers, tubes, micelles, gels and the like by utilizing intermolecular forces such as hydrogen bond action, hydrophilic and hydrophobic action, electrostatic action, pi-pi stacking and the like. In earlier researches, a polypeptide-drug conjugate formed by covalent coupling of a functional polypeptide capable of self-assembling to form nano-fibers or gel and a chemical drug with an anti-tumor effect can be used for in-situ injection of solid tumors, and can realize long-term retention at tumor parts to play a long-acting slow-release effect. However, the nanofiber and the nanogel have certain risks in intravenous injection, and are difficult to be clinically used for intravenous injection administration.
The nano particles or the micelles can be used for systemic administration, and due to the EPR effect at the tumor part, the nano particles or the micelles can well penetrate out of capillaries and enter tumor cells, but the retention time at the tumor part is far shorter than that of nano fibers. In order to further develop the application of the polypeptide-drug conjugate in the aspect of anti-tumor intravenous injection treatment, how to make the polypeptide-drug conjugate meet the requirement of intravenous injection administration and have long-term retention capacity is the focus of the current drug development.
Disclosure of Invention
In order to overcome the defects of antitumor drugs in the prior art, the invention designs a nanoparticle compound with tumor microenvironment responsive deformation, which is different from a covalent connection mode in the prior art, and an amphiphilic oligomeric polypeptide drug conjugate of the nanoparticle compound is combined with beta-carboxamide polylysine through electrostatic interaction. Under the condition of tumor acidic pH, the polylysine of the beta-carboxylic acid amide group of the nanoparticle compound is subjected to charge reversal, the nanoparticle compound is dissociated under the electrostatic action, and the amphiphilic oligomeric polypeptide drug conjugate is released and further assembled into long fibers, so that the effects of long-time retention of tumor parts and tumor metastasis inhibition are achieved.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
an amphiphilic oligomeric polypeptide drug conjugate is characterized in that an amino acid sequence is shown in SEQ ID No:1 and adriamycin through chemical bond condensation.
The preferable chemical bond of the amphiphilic oligomeric polypeptide drug conjugate is an amido bond or an ester bond.
In a preferred technical scheme, an amido bond or an ester bond is formed between an amino group or a hydroxyl group in the doxorubicin molecular structure and a carboxyl group at the C-terminal of the oligomeric polypeptide, or the carboxyl group at the C-terminal of the oligomeric polypeptide is converted into an amido group or an ester group, and the amino group at the N-terminal reacts with dianhydride to form a carboxyl group, and then forms an amido bond or an ester bond with the amino group or the hydroxyl group in the doxorubicin molecular structure. The dianhydride is selected from malonic anhydride, succinic anhydride, glutaric anhydride or adipic anhydride.
In a preferred technical scheme, the amphiphilic oligomeric polypeptide drug conjugate is Dox-Suc-K (Fmoc) IGLFRWR, and the structural formula is as follows:
the amphiphilic oligomeric polypeptide drug conjugate can be assembled with beta-carboxyamide polylysine to form nanoparticles through electrostatic interaction, and can be self-assembled to form fibers under the condition of tumor weak acid environment.
The invention provides a nano particle compound with responsive deformation of tumor microenvironment, which is formed by combining an amphiphilic oligomeric polypeptide drug conjugate with beta-carboxamide polylysine through electrostatic interaction.
Based on the characteristics of the nanoparticle complex, the invention provides an anti-tumor medicament which contains the nanoparticle complex as an active ingredient. Furthermore, the anti-tumor medicine also comprises a pharmaceutically acceptable carrier.
The anti-tumor drug is preferably an intravenous injection.
The invention also aims to provide application of the beta-carboxyamide polylysine in inducing morphological transformation between long fibers and nanoparticles of the amphiphilic oligomeric polypeptide or the amphiphilic oligomeric polypeptide drug conjugate.
The invention also aims to provide an oligomeric polypeptide, and an amino acid sequence is shown as SEQ ID No:1 is shown.
The invention has the beneficial effects that:
the invention designs an amphiphilic oligomeric polypeptide drug conjugate with the capability of forming fibers by self-assembly by utilizing the characteristic that beta-carboxylic acid amide polylysine has a pH response type charge reversal function, and the beta-carboxylic acid amide polylysine can form a nano particle compound through electrostatic interaction with the beta-carboxylic acid amide polylysine to block the self-assembly behavior of the nano particle compound, so that the nano micelle capable of being injected intravenously is formed. After intravenous injection, the nano particle compound is passively targeted to a tumor part, under the environment of low pH value of the tumor part, a beta-carboxylic acid amide group on beta-carboxylic acid amide polylysine on the nano particle compound leaves, so that a polymer is converted from negative charge to positive charge to generate charge inversion, the nano particle compound is dissociated under the action of electrostatic repulsion to release an amphiphilic oligomeric polypeptide drug conjugate, the assembly performance is recovered, the nano particle compound is locally aggregated on the tumor to form a long fiber structure, and the nano particle compound is retained in tumor tissues for a long time to achieve the effect of long-acting treatment.
The nanoparticle compound can realize intravenous injection administration of the antitumor drug, and can be slowly degraded in vivo to release the inner core antitumor drug and exert antitumor effect.
The nanoparticle compound disclosed by the invention is stable in structure, high in drug loading capacity and small in side effect, and provides a new strategy for tumor treatment.
Drawings
FIG. 1 is a mass spectrum of Dox-Suc-KIGLFRWR prepared according to the present invention.
FIG. 2 is a transmission electron microscope inspection of the Dox-Suc-KIGLFRWR self-assembly prepared by the present invention.
FIG. 3 is a spectrum of beta-carboxyamide polylysine (FB) MALDI-TOF MS.
FIG. 4 shows the Zeta potential change of the beta-carboxyamide polylysine (FB) at different pH values.
FIG. 5 shows the particle size of nanoparticles at different ratios of Dox-Suc-KIGLFRWR to β -carboxyamide polylysine.
FIG. 6 Zeta potentials of nanoparticle complexes FDSPC-NPs according to the invention constructed at a molar ratio of 1.
FIG. 7 particle size of nanoparticle complexes FDSPC-NPs according to the present invention constructed at a molar ratio of 1.
FIG. 8 is the creation of the Dox-Suc-KIGLFRWR standard curve in example 5.
FIG. 9 is the creation of DOX standard curve in example 5.
FIG. 10 is a graph showing the cumulative release of FDPC-NPs from example 5 at various pH buffers.
FIG. 11 is a transmission electron microscopy of the self-assembly of FDSPC-NPs at different pH values in example 6.
FIG. 12 is an in vitro apoptosis assay of FDSPC-NPs in example 7.
Detailed Description
The following examples are provided to illustrate specific steps of the present invention, but are not intended to limit the scope of the invention.
The terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art, unless otherwise specified.
The present invention is described in further detail below with reference to specific examples and with reference to the data. It will be understood that these examples are intended to illustrate the invention and are not intended to limit the scope of the invention in any way.
In the following examples, various procedures and methods not described in detail are conventional methods well known in the art.
The present invention is further illustrated by the following specific examples.
Example 1: preparation of amphiphilic oligomeric polypeptide drug conjugate Dox-Suc-KIGLFRWR
1. Material
9-fluorenylmethoxycarbonyl (Fmoc) protected glycine (G), fmoc protected phenylalanine (F), fmoc and tert-butyloxycarbonyl (Boc) protected tryptophan (W), fmoc protected leucine (L), fmoc and 2,4,6, 7-pentamethyl-2H-benzofuran-5-sulfonyl (Pbf) protected arginine (R), fmoc protected isoleucine (I), fmoc and 2- (4, 4-dimethyl-2, 6-dioxocyclohexylmethylene) ethyl protected lysine (K), rink Amide-AM Resin (100-200 mesh, substitution coefficient: 0.486 mmol/G), O-benzotriazol-tetramethyluronium hexafluorophosphate (HBTU, 99%); n, N-diisopropylethylamine (DIEA, 99%); piperidine (Piperidine, 99%), N-dimethylformamide (DMF, 99%), triethylamine; triisopropylsilane (Tis, 99%); trifluoroacetic acid (TFA, 99%).
2. Preparation method
The oligomeric polypeptide is synthesized by a conventional solid-phase synthesis method, and then the drug is coupled. The method comprises the following specific steps:
(1) synthesis of Suc-K (Fmoc) IGLFRWR:
Fmoc-K (Dde) -IGLFRWR-Resin is obtained by utilizing a Focus XC full-automatic polypeptide synthesizer (AAPPTEC) to synthesize, is washed for 3 times by DMF, is detected by a ninhydrin color development method, and does not develop blue to prove that the reaction is complete. Then, the Dde protection is removed by reaction with 1% -2% hydrazine hydrate solution, the reaction is repeated for 3 times, each time for 3 minutes, and the detection is carried out by a ninhydrin color development method, and the color is blue. The obtained Resin peptide Fmoc-KIGLFRWR-Resin was weighed to calculate the theoretical molar number, and succinic anhydride (Suc) and triethylamine were added to the Resin peptide in a charge ratio (Resin peptide: succinic anhydride: triethylamine =1 2. N is a radical of 2 Stirring at room temperature for 1 hr under protection, filtering with sand core funnel, discarding filtrate, washing the obtained resin product with DMF for 5 times to obtain HOOCCH 2 CH 2 CO-K (Fmoc) IGLFRWR-Resin (abbreviated as Suc-K (Fmoc) IGLFRWR-Resin) was detected with ninhydrin and no color was observed to confirm completion of the reaction. After weighing, the samples were transferred to a 50mL centrifuge tube and added to a cleavage solution (TFA: tis: water =95 = 2.5 2 CH 2 Cutting CO-K (Fmoc) IGLFRWR from the resin, oscillating and cutting for 90min, filtering by a sand core funnel to collect filtrate, pouring the filtrate into 100mL of glacial ethyl ether (precooling for 2h at (-80 ℃), standing for 30min,10000rpm,6 ℃, centrifuging for 5min, discarding supernatant, washing precipitates with ethyl ether for 5 times, performing vacuum drying to obtain Suc-K (Fmoc) IGLFRWR (crude product, purifying the prepared liquid phase, and performing freeze drying to obtain a pure product.
(2) Synthesis of Dox-Suc-KIGLFRWR:
taking a pure Suc-K (Fmoc) IGLFRWR, taking anhydrous DMF as a solvent, adding PyAop and DIEA to the Suc-K (Fmoc) IGLFRWR according to a charge ratio (Suc-K (Fmoc) IGLFRWR: pyAop: DIEA = 1) 2 Stirring and activating in ice-water bath for 2-3h under protection, adding doxorubicin hydrochloride with 3 times of equivalent weight, and adding N 2 The reaction was stirred under protection from light for 1 day. Then the mixture is loaded into a 50mL centrifuge tube, 20Ml 20% piperidine is added into the centrifuge tube to react, fmoc protection is removed, after shaking for 5min, the reaction is drained, the reaction is repeated for 1 time, methanol is washed for 3 times, and the drainage is carried out. The crude product was purified by preparative liquid phase and identified by ESI-MS.
Mass spectrometry (ESI-MS) measurements are shown in FIG. 1, which gives molecular weight peaks of 850.928 and 1700.847 for double and single charge, respectively, whose calculated molecular weights match the theoretical molecular weights, indicating that the chemical structure of the compound is correct.
Example 2: transmission Electron Microscopy (TEM) examination of Dox-Suc-KIGLFRWR self-Assembly
Preparing Dox-Suc-KIGLFRWR solution with the concentration of 100 mu M, assembling for 0,1,6 and 12h, dripping the solution on a copper net coated with a support film, staying for 60s, sucking off redundant solution by using filter paper, adding a drop of saturated uranium acetate coloring agent respectively, negatively dyeing for 90s, sucking off redundant dyeing liquid by using the filter paper, naturally drying, and observing under a transmission electron microscope, wherein the electron microscope images of assembling for 0h, 1h, 3h and 6h are respectively shown from left to right in the figure 2. As can be seen from the figure, the polypeptide-drug conjugate is self-assembled to form 40-50nm spherical micelles at 0h, the micelles are further aggregated to form primary fibers after 1h, and the fibers are intertwined and aggregated after 6h, which shows that the synthesized polypeptide-drug conjugate has good self-assembly capability.
Example 3: preparation of FB-Dox-Suc-KIGLFRWR-NPs
1. Material
2, 3-Dimethylmaleic anhydride (DMMA, 99%), ε -polylysine (ε -PL, mw: 3000-5000), triethylamine, N-hydroxysuccinimide (NHS, 99%), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI, 99%); general dialysis bag (molecular weight 2000D), pure water, glacial acetic acid.
2. Preparation method
(1) Synthesis of β -carboxylic acid amide polylysine (FB):
adding 180mg of DMMA into 15mL of epsilon-polylysine aqueous solution dissolved with 160mg, adding triethylamine to adjust the pH value to be alkaline, stirring and dissolving, adding 190mg of NHS, dissolving, adding 240mg of EDCI, stirring and adding triethylamine, keeping the pH value of a reaction system to be 8.5-9, and reacting overnight. Transferring the reaction solution into an activated dialysis bag (molecular weight 2000D), dialyzing for 12h by using pure water as a dialysis medium at a volume ratio of 1. And freeze-drying the dialyzed reaction solution to obtain functional beta-carboxylic acid amide polylysine (FB) with charge reversal characteristics. The molecular weight of the product FB was analyzed by MALDI-TOF MS.
FB was detected by MALDI-TOF MS, see FIG. 3, and the molecular weight of FB obtained by synthesis was mainly distributed in 5500-7200, and the molecular weight was increased by nearly 2000 compared with that of polylysine, which is a raw material, indicating that a large amount of DMMA was covalently modified on polylysine.
FB Zeta potential changes at different pH values:
preparing FB solutions (5 mg/mL) with different pH values (pH =3,4,5,6,7,8, 9) in parallel respectively, and determining the Zeta values of the FB in the solutions with different pH values; meanwhile, an unmodified raw material drug epsilon-polylysine solution is used as a control group, epsilon-polylysine solutions (3.5 mg/mL) with different pH values (pH =3,4,5,6,7,8, 9) are respectively prepared in parallel, and the Zeta values of epsilon-polylysine in the solutions with different pH values are measured. Each sample was assayed 3 times in parallel and the average was taken as the assay result, see fig. 4. The functional material FB has electronegativity under physiological conditions (pH = 7.4), the FB charge is reversed to be positive when the pH is lower than 6.95, and the Zeta potential is rapidly increased along with the reduction of the pH value, which indicates that the synthesized FB has good weak acid sensitivity.
(2) Synthesis of FB-Dox-Suc-KIGLFRWR-NPs (FDSPC-NPs):
taking 4 test tubes, calculating the molar ratio of Dox-Suc-KIGLFRWR (PDC) to the polylysine connected with the beta-carboxylic acid amide (FB) according to the molar ratio of 1, 2,1, 3, weighing FB 0.00,6.50, 13.00 and 19.50mg, respectively adding the FB 0.00,6.50, 13.00 and 19.50mg into the test tubes, sequentially adding 2mL of ultrapure water into each test tube for dissolving, then respectively adding PDC 1.70mg, adjusting the pH to be neutral by using 0.1M hydrochloric acid and sodium hydroxide solution after dissolving, respectively measuring the particle sizes of the test tubes in 0,1,3,6 and 12 hours, and observing the change of the particle sizes of the self-assembly system along with the ratio of the two test tubes. The result is shown in fig. 5, the self-assembly particle size of the nanoparticles gradually increases in speed and degree with the increase of the addition ratio of the polymer material, which indicates that the addition of the polymer material can limit the growth of the polypeptide-drug conjugate nanofibers. When the proportion of the high polymer material is more than or equal to 2, the particle size of the nano particles is not increased along with the prolonging of the time, but the proportion of the added high polymer material is increased, and the particle size of the system is slightly increased. Therefore, PDC: FB =1:2 is the optimal ratio for the construction of FDSPC-NPs.
The particle size and Zeta potential were determined by constructing FDSPC-NPs at a concentration of 100. Mu.M at a molar ratio of 1. As a result, as shown in FIGS. 6 and 7, the particle size distribution of FDSPC-NPs was about 80nm, the particle size distribution was uniform (PDI = 0.165), and the average potential of the FDSPC-NPs band was-9.03 mv.
Under the neutral condition, dox-Suc-KIGLFRWR takes positive charge as a core molecule of the inner layer, FB takes negative charge as a shell molecule, and FDSPC-NPs can be formed between the Dox-Suc-KIGLFRWR and the FB through electrostatic force.
Example 5: in vitro Release study of FDSPC-NPs
(1) Establishment of Dox-Suc-KIGLFRWR standard curve
Accurately weighing 16.99mg of Dox-Suc-KIGLFRWR pure product, placing the product in a 10mL volumetric flask, adding a proper amount of methanol to dissolve DSPC, fixing the volume of methanol to a scale, shaking up to obtain a stock solution with a molar concentration of 1mM, and storing the stock solution at 4.0 ℃ for later use. Precisely measuring appropriate amount of stock solutions, placing in 65 mL volumetric flasks, adding appropriate amount of methanol to dilute to scale, shaking to obtain solutions with molar concentrations of 2.5,5,10,50,100,250 μ M, respectively, recording peak areas by High Performance Liquid Chromatography (HPLC), and drawing standard curve, see FIG. 8.
(2) Establishment of DOX Standard Curve
Accurately weighing 5.80mg of DOX standard substance, placing in a 10mL volumetric flask, adding a proper amount of methanol to dissolve, fixing the volume to a scale, shaking up to obtain a stock solution with a molar concentration of 500 mu M, and storing at 4.0 ℃ for later use. Precisely measuring an appropriate amount of the stock solutions, placing the stock solutions in 6 volumetric flasks with the volume of 5mL, adding an appropriate amount of methanol to dilute the stock solutions to a scale, shaking the stock solutions evenly to obtain standard solutions with the molar concentrations of 2.5,5,10,50,100 and 250 mu M respectively, recording peak areas by High Performance Liquid Chromatography (HPLC), and drawing a standard curve, which is shown in a figure 9.
(3) In vitro release behavior of different pH buffer solutions FDPC-NPs
1mL of each of FDPC-NPs and DOX solutions with a concentration of 1mM was prepared, and placed in an activated dialysis bag (1000D), 10mL of neutral PBS (pH 7.4) and acidic PBS (pH 6.5) were used as dialysis media, and the tubes of each group were placed in a constant temperature oscillator, and subjected to in vitro release investigation at 37 ℃ for 100r min-1. Sampling for 0.25,0.5,1,3,6, 12, 24, 48, 72, 96, 120 and 144 hours respectively, wherein the sampling volume is 0.3mL, supplementing an equal volume of isothermal fresh release medium after sampling, centrifuging a sample for 5min at 5000r min-1, and after carrying out sample injection analysis through high performance liquid chromatography, respectively substituting the samples into the standard curve concentrations of DPCs and DOX under 2.5.1.4 items. The cumulative release rates of DPCs and DOX were calculated according to the formula, 3 replicates of each sample were prepared, run in parallel, averaged, and the in vitro release curves of FDPC-NPs were plotted, see FIG. 10. The result shows that the release rate of the prepared FDPC-NPs is higher under a weakly acidic condition (pH 6.5), the cumulative release rate of 12h reaches 50%, the release rate is slowed down after 12h, and the cumulative release rate of 196h reaches 85%; under the neutral condition (pH 7.4), the release is slowly released, the cumulative release rate after 12h only reaches 5 percent, and the cumulative release rate after 196h is less than 50 percent. The result proves that the constructed FDPC-NPs have good acid-responsive slow-release function.
Example 6: transmission Electron Microscopy (TEM) examination of self-Assembly of FDSPC-NPs at different pH values
FDSPC-NPs solution was prepared at a concentration of 100. Mu.M, pH-adjusted to neutral (7.0) with 0.1M hydrochloric acid and sodium hydroxide solution, and TEM samples were taken at 0.5 h. After 4h, the solution was divided into 2 portions, one portion was kept at the original neutral pH and sampled for 12h to prepare TEM samples, and the other portion was adjusted to pH6.5 with 0.1M hydrochloric acid and sodium hydroxide solution and sampled for 0.5h and 12h to prepare TEM samples. Observed by a transmission electron microscope, see FIG. 11, from left to right are electron micrographs of pH7.0-0.5h, pH7.0-12h, pH6.5-0.5h and pH6.5-12h, respectively. It can be seen that FDSPC-NPs can aggregate to form injectable nanospherical structures (40-50 nm) under neutral conditions and can self-assemble responsively to form fibrous structures under mildly acidic conditions.
Example 7: FDSPC-NPs in vitro apoptosis assay
The apoptosis effect of different concentrations of DOX and FDSPC-NPs prepared in example 3 on SMMC7721 cells was examined by Annexin-V FITC/PI apoptosis detection kit. After counting SMMC7721 in logarithmic growth phase, cells were counted at 2X 10 5 Inoculating each cell in 6-well plate, adding 2mL of whole culture medium into each well, culturing, and placing the inoculated cells at 37 deg.C with CO 2 The cells were incubated at 5% saturation humidity for 24 hours, and the culture broth was aspirated and washed 3 times with PBS. Adding 2mL of DOX and FDSPC-NPs single culture diluent with different concentrations into each well, incubating for 24h, carefully sucking the upper layer of drug-containing culture solution into a 4mL centrifuge tube, digesting each well with 0.5mL of trypsin without EDTA for 4min, adding 0.5mL of total culture medium to stop digestion, respectively collecting cells from each well, mixing with the corresponding drug-containing culture solution, and culturing at 2000rmin -1 And centrifuging for 5min. The supernatant was carefully aspirated and the cells were washed 1 time with ice PBS. Adding 195 mu L of Annexin-V working solution into each tube of cells to resuspend the cells, adding 5 mu L of Annexin-V FITC, mixing uniformly, adding 10 mu L of PI, mixing uniformly, reacting at room temperature in a dark place for 10min, and detecting the sample by using a flow cytometer. Cells were incubated with single medium cultured cells as control. Detection ofResults referring to fig. 12, the apoptosis rate was significantly increased in the FDPC-NPs and DOX groups compared to the control group (p < 0.01), and the apoptosis rate was gradually increased in each group with increasing dosing concentration (calculated as DOX concentration). The FDPC-NPs and DOX have obvious apoptosis promoting effect on SMMC7721 liver cancer cells; compared with the DOX group, the FDPC-NPs have no statistical difference in apoptosis rate under the same concentration (calculated by DOX concentration), which indicates that the FDPC-NPs have the tumor killing effect equivalent to DOX.
Example 8
The injection is prepared by a conventional pharmaceutical method and is used for the anti-tumor treatment of solid tumors. The experimental result shows that the preparation has good inhibition effect on liver cancer cells.
Sequence listing
<110> Nanjing university of traditional Chinese medicine
Nanjing haikerui Pharmaceutical Technology Co.,Ltd.
<120> nanoparticle complex for responsive deformation of tumor microenvironment
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Lys Ile Gly Leu Phe Arg Trp Arg
1 5
Claims (4)
1. A nanoparticle complex for responsive deformation of a tumor microenvironment, characterized by the structural formula:
2. An antitumor agent characterized by comprising the tumor microenvironment-responsively deformable nanoparticle complex of claim 1 as an active ingredient.
3. Antitumor drug according to claim 2, characterized in that it is an intravenous injection.
4. The application of beta-carboxyamide polylysine in preparing a reagent for transforming the appearance between long fibers and nanoparticles of an amphiphilic oligomeric polypeptide drug conjugate is characterized in that the amphiphilic oligomeric polypeptide drug conjugate has the following structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910396302.8A CN111939268B (en) | 2019-05-14 | 2019-05-14 | Nano particle compound for responsive deformation of tumor microenvironment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910396302.8A CN111939268B (en) | 2019-05-14 | 2019-05-14 | Nano particle compound for responsive deformation of tumor microenvironment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111939268A CN111939268A (en) | 2020-11-17 |
| CN111939268B true CN111939268B (en) | 2023-03-31 |
Family
ID=73335368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910396302.8A Active CN111939268B (en) | 2019-05-14 | 2019-05-14 | Nano particle compound for responsive deformation of tumor microenvironment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111939268B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807326B (en) * | 2021-01-15 | 2022-08-19 | 上海多肽生物技术有限公司 | Polypeptide nano-composite and preparation method and application thereof |
| CN112940248B (en) * | 2021-02-04 | 2023-07-18 | 西安交通大学 | PH responsive metal coordination polymer prodrug nano-particle and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148289A (en) * | 2015-09-30 | 2015-12-16 | 南京中医药大学 | Amphipathic oligomeric polypeptide drug conjugate |
| CN105288653A (en) * | 2015-11-19 | 2016-02-03 | 南京中医药大学 | Amphiphilic oligopeptide drug conjugate |
| CN105561332A (en) * | 2016-01-29 | 2016-05-11 | 浙江工业大学 | Polylysine nano prodrug micelle with charge turning and targeting functions and preparation and application thereof |
| CN106667962A (en) * | 2016-12-30 | 2017-05-17 | 深圳大学 | Charge conversion type nanometer drug carrier and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108938663B (en) * | 2017-05-26 | 2021-07-09 | 南开大学 | 1, 2-dicarboxylic acid monoamide polymers as potentiators for chemotherapy |
-
2019
- 2019-05-14 CN CN201910396302.8A patent/CN111939268B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148289A (en) * | 2015-09-30 | 2015-12-16 | 南京中医药大学 | Amphipathic oligomeric polypeptide drug conjugate |
| CN105288653A (en) * | 2015-11-19 | 2016-02-03 | 南京中医药大学 | Amphiphilic oligopeptide drug conjugate |
| CN105561332A (en) * | 2016-01-29 | 2016-05-11 | 浙江工业大学 | Polylysine nano prodrug micelle with charge turning and targeting functions and preparation and application thereof |
| CN106667962A (en) * | 2016-12-30 | 2017-05-17 | 深圳大学 | Charge conversion type nanometer drug carrier and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Dual-pH Sensitive Charge-Reversal Polypeptide Micelles for Tumor-Triggered Targeting Uptake and Nuclear Drug Delivery;Shi-Song Han，et al.;《small》;20150127;第11卷(第21期);2543-2554 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111939268A (en) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhong et al. | Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy | |
| Zhong et al. | Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo | |
| KR102190093B1 (en) | Biodegradable amphiphilic polymers specifically targeting ovarian cancer, polymer cyclists prepared therefrom, and uses | |
| An et al. | A sulfur dioxide polymer prodrug showing combined effect with doxorubicin in combating subcutaneous and metastatic melanoma | |
| CN111939268B (en) | Nano particle compound for responsive deformation of tumor microenvironment | |
| US20200262981A1 (en) | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same | |
| WO2019061561A1 (en) | Medicament delivery system, and preparation method and application thereof | |
| CN106632695B (en) | pH-sensitive polypeptide and application thereof | |
| WO2021232846A1 (en) | Zwitterionic polypeptide and derivatives thereof, and nano-drug based on same | |
| CN110604820B (en) | Double-sensitive polymer-drug connector and preparation method and application thereof | |
| CN106729727A (en) | Reduction response type magnetic nano-carrier of targeting ligand modification and preparation method thereof | |
| CN107266384B (en) | N- carboxyl inner-acid anhydride monomer and polyaminoacid based on 2- aminohexadecanoic acid and preparation method thereof | |
| CN113633785A (en) | Preparation method and application of intelligent responsive shell-core polyelectrolyte nanogel | |
| CN103083682B (en) | Folic acid modified chitosan quaternary ammonium salt-taxol polymer medicine, as well as preparation method and application thereof | |
| CN108653743A (en) | Double target liposomes of a kind of heart and brain and its preparation method and application | |
| CN109908105B (en) | Deoxycholic acid modified nano compound and preparation and application thereof | |
| CN113069416B (en) | Active targeting amphiphilic polypeptide composite nano micelle prodrug and preparation and application thereof | |
| CN107028882B (en) | Physically-wrapped tumor-targeted nano drug delivery system, and preparation method and application thereof | |
| CN108484733A (en) | Amphiphilic targeting cell-penetrating peptide and its nano-probe, the drug-loading nanoparticles of self assembly | |
| KR20120126356A (en) | Nanoparticles comprising amphiphilic low molecular weight hyaluronic acid complex and a process for the preparation thereof | |
| CN111454257B (en) | Small molecule prodrug composed of pH-sensitive orthoester and dasatinib conjugate and preparation method thereof | |
| CN114903872B (en) | Dendrimer self-assembly body for co-delivering tripterine and Bcl-2-functional conversion peptide, and preparation method and application thereof | |
| US11786525B1 (en) | High-efficiency anti-tumor nano-drug delivery system containing hydralazine and preparation method thereof | |
| CN114380991B (en) | Polymer-lipid conjugate and preparation method and application thereof | |
| CN114159581B (en) | Polypeptide hydrogel and application thereof in preparation of tumor treatment drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |